ImageneBio Reports Third Quarter 2026 Financial Results
ImageneBio Q3 EPS $(0.91) Misses $(0.83) Estimate
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
HC Wainwright & Co. Initiates Coverage On ImageneBio with Buy Rating, Announces Price Target of $28
ImageneBio Files Prospectus For Offering $200M Mixed Shelf
ImageneBio Reports Second Quarter 2026 Financial Results
ImageneBio Q2 EPS $(0.63) Beats $(1.05) Estimate
ImageneBio Appoints Matt Robbins as General Counsel
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
Wedbush Reiterates Underperform on ImageneBio, Maintains $2 Price Target
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
ImageneBio Q1 EPS $(0.95) Misses $(0.70) Estimate
ImageneBio $30 Million Private Placement Ignites Stock
ImageneBio Announces $30 Million Private Placement
ImageneBio shares are trading higher after the company announced it entered into a $30 million definitive securities purchase agreement with certain institutional investors in a private placement.
ImageneBio Raises $30M Via Private Institutional Placement To Fund Hair Loss And Skin Disease Treatments
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.